Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a 7-Day antibiotic course replace 3 weeks for silent STI?

NCT ID NCT07767422

Disease control Sponsor: University Hospital, Bordeaux Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 17, 2026 · Last updated Aug 18, 2026 · Updated 1 time

Summary

This trial tests whether a 7-day course of doxycycline can effectively cure asymptomatic anal lymphogranuloma venereum (LGV), a sexually transmitted infection caused by Chlamydia trachomatis. Currently, treatment lasts 21 days, but recent studies suggest a shorter course may work. The study will enroll 120 men with asymptomatic anal LGV, give them doxycycline 200 mg daily for 7 days, and check for microbiological cure four weeks later.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
doxycycline
What this could lead to
If successful, this could shorten treatment for asymptomatic anal LGV from 21 days to 7 days, simplifying care and reducing antibiotic use.
What could go wrong
The trial is small and early-stage, and the shorter course may not fully clear the infection in all cases, potentially leading to treatment failure or reinfection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Nov 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years * Male sex at birth * LGV-positive result on anal specimen using Nucleic Acid Amplification Test at screening * Having taken at least doxycycline for two days (i.e 400 mg of doxycycline) * Not having taken more than 7 days of doxycycline 200 mg per day * No more than 12 days between the date of sampling and date of inclusion * No anorectal symptoms * Individual available for participation and follow-up during the four weeks required for the study * Affiliate or beneficiary of a social security scheme * Free written informed consent signed by the participant or by a legal representative (in the event of the participant's inability to consent) and the investigator (no later than the day of inclusion and before any examination required by the research). Exclusion Criteria: * Individual with anorectal symptoms * Antibiotic treatment with antichlamydial activity (fluoroquinolones, macrolides-lincosamides-streptogramins, tetracyclines and rifampicin) within 28 days before the screening visit * Use of doxycycline post-exposure prophylaxis (Doxy-PEP) * Participation in another study * Individual under a measure of legal protection measure (safeguard of justice, guardianship or curatorship) or unable to consent * Refusal to participate in the study * Mental state rendering the person giving consent incapable of understanding the entirety of the trial * Participant detained by judicial or administrative decision. * Individual receiving an anticoagulant therapy * Individual with a history of known hypersensitivity to doxycycline or any other antibiotic of the tetracycline family or allergy to any of the excipients (Hydrogenated castor oil, povidone, anhydrous colloidal silica, magnesium stearate, microcrystalline cellulose, sodium carboxymethyl starch (type A)). * Individual treated with retinoids by general route. * Individual receiving 10,000 IU of vitamin A per day or more * Individual being a relative of the investigator or a relative of someone from the team directly involved in the trial, including assistant doctors, pharmacists, nurses, and trial coordinators

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Doxycycline are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

lymphogranuloma venereum

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Doxycycline Lymphogranuloma venereum No anorectal symptoms

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    14 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Centre Hospitalier de Tourcoing, Ceggid

    Tourcoing, 59208, France

  • Centre Hospitalier de Tourcoing, Service Des Maladies Infectieuses Et Tropicales

    Tourcoing, 59208, France

  • Chu Toulouse Purpan, Service Des Maladies Infectieuses Et Tropicales

    Toulouse, 31059, France

  • Chu de Nantes, Maladies Infectieuses (Cpmit)

    Nantes, 44093, France

  • Hopital Bichat - Claude Bernard, Ceggid

    Paris, 75018, France

  • Hopital Bichat - Claude Bernard, Service Des Maladies Infectieuses Et Tropicales

    Paris, 75018, France

  • Hopital François Mitterrand, Centres Gratuits D'Information, de Depistage Et de Diagnostic (Ceggid)

    Dijon, 21079, France

  • Hopital Intercommunal Andre Gregoire - Ght , Centres Gratuits D'Information, de Depistage Et de Diagnostic (Ceggid)

    Montreuil, 93100, France

  • Hopital La Pite Salpetriere, Service Des Maladies Infectieuses Et Tropicales

    Paris, 75013, France

  • Hopital Saint-Louis, Service Des Maladies Infectieuses Et Tropicales

    Paris, France

  • Hospices Civils de Lyon, Centres Gratuits D'Information, de Depistage Et de Diagnostic (Ceggid)

    Lyon, 69004, France

  • Hotel-Dieu, Service Des Maladies Infectieuses Et Tropicales

    Paris, 75004, France

  • Service de Prevention Aupres Des Jeunes, Ceggid

    Marseille, 13331, France

  • University Hospital, Bordeaux, Department of Infectious Diseases

    Bordeaux, 33000, France